Connection
Eric Peterson to Animals
This is a "connection" page, showing publications Eric Peterson has written about Animals.
|
|
Connection Strength |
|
 |
|
 |
|
0.404 |
|
|
|
-
Hay CE, Ewing LE, Hambuchen MD, Zintner SM, Small JC, Bolden CT, Fantegrossi WE, Margaritis P, Owens SM, Peterson EC. The Development and Characterization of an scFv-Fc Fusion-Based Gene Therapy to Reduce the Psychostimulant Effects of Methamphetamine Abuse. J Pharmacol Exp Ther. 2020 07; 374(1):16-23.
Score: 0.069
-
Hay CE, Gonzalez GA, Ewing LE, Reichard EE, Hambuchen MD, Nanaware-Kharade N, Alam S, Bolden CT, Owens SM, Margaritis P, Peterson EC. Development and testing of AAV-delivered single-chain variable fragments for the treatment of methamphetamine abuse. PLoS One. 2018; 13(6):e0200060.
Score: 0.061
-
Reichard EE, Nanaware-Kharade N, Gonzalez GA, Thakkar S, Owens SM, Peterson EC. PEGylation of a High-Affinity Anti-(+)Methamphetamine Single Chain Antibody Fragment Extends Functional Half-Life by Reducing Clearance. Pharm Res. 2016 12; 33(12):2954-2966.
Score: 0.054
-
Nanaware-Kharade N, Thakkar S, Gonzalez GA, Peterson EC. A Nanotechnology-Based Platform for Extending the Pharmacokinetic and Binding Properties of Anti-methamphetamine Antibody Fragments. Sci Rep. 2015 Jul 10; 5:12060.
Score: 0.050
-
Peterson EC, Gentry WB, Owens SM. Customizing monoclonal antibodies for the treatment of methamphetamine abuse: current and future applications. Adv Pharmacol. 2014; 69:107-27.
Score: 0.045
-
Peterson EC, Gunnell M, Che Y, Goforth RL, Carroll FI, Henry R, Liu H, Owens SM. Using hapten design to discover therapeutic monoclonal antibodies for treating methamphetamine abuse. J Pharmacol Exp Ther. 2007 Jul; 322(1):30-9.
Score: 0.028
-
Chappell K, Graw S, Washam CL, Storey AJ, Bolden C, Peterson EC, Byrum SD. PTMViz: a tool for analyzing and visualizing histone post translational modification data. BMC Bioinformatics. 2021 May 26; 22(1):275.
Score: 0.019
-
Li W, Chen C, Drelich A, Martinez DR, Gralinski LE, Sun Z, Sch?fer A, Kulkarni SS, Liu X, Leist SR, Zhelev DV, Zhang L, Kim YJ, Peterson EC, Conard A, Mellors JW, Tseng CK, Falzarano D, Baric RS, Dimitrov DS. Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection. Proc Natl Acad Sci U S A. 2020 11 24; 117(47):29832-29838.
Score: 0.018
-
Li W, Sch?fer A, Kulkarni SS, Liu X, Martinez DR, Chen C, Sun Z, Leist SR, Drelich A, Zhang L, Ura ML, Berezuk A, Chittori S, Leopold K, Mannar D, Srivastava SS, Zhu X, Peterson EC, Tseng CT, Mellors JW, Falzarano D, Subramaniam S, Baric RS, Dimitrov DS. High Potency of a Bivalent Human VH Domain in SARS-CoV-2 Animal Models. Cell. 2020 10 15; 183(2):429-441.e16.
Score: 0.018
-
McClenahan SJ, Kormos CM, Gunnell M, Hambuchen MD, Lamb P, Carroll FI, Lewin AH, Peterson EC, Owens SM. Design, synthesis and biological evaluation of a bi-specific vaccine against a-pyrrolidinovalerophenone (a-PVP) and 3,4-methylenedioxypyrovalerone (MDPV) in rats. Vaccine. 2020 01 10; 38(2):336-344.
Score: 0.017
-
Carroll FI, Blough BE, Pidaparthi RR, Abraham P, Gong PK, Deng L, Huang X, Gunnell M, Lay JO, Peterson EC, Owens SM. Synthesis of mercapto-(+)-methamphetamine haptens and their use for obtaining improved epitope density on (+)-methamphetamine conjugate vaccines. J Med Chem. 2011 Jul 28; 54(14):5221-8.
Score: 0.009
-
DeKeyser JG, Laurenzana EM, Peterson EC, Chen T, Omiecinski CJ. Selective phthalate activation of naturally occurring human constitutive androstane receptor splice variants and the pregnane X receptor. Toxicol Sci. 2011 Apr; 120(2):381-91.
Score: 0.009
-
Carroll FI, Abraham P, Gong PK, Pidaparthi RR, Blough BE, Che Y, Hampton A, Gunnell M, Lay JO, Peterson EC, Owens SM. The synthesis of haptens and their use for the development of monoclonal antibodies for treating methamphetamine abuse. J Med Chem. 2009 Nov 26; 52(22):7301-9.
Score: 0.008
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|